Home / Production Assistant, Diabetes In Control (page 93)

Production Assistant, Diabetes In Control

December 3, 2016

Test Your Knowledge

This injectable drug class focuses on the incretin system and leads to increased insulin secretion, decreased glucagon secretion, and slowed gastric emptying. One of its advantages is that its use can lead to weight loss: 1. GLP-1 receptor agonists 2. SGLT-2 Inhibitors 3. DPP-IV 4. Sulfonylureas Did you get the right answer? Follow the link to find out!

Read More »

ACA Changes

Do you feel that with our new president, changes to the Affordable Care Act will be: 1. Negative 2. Positive 3. Unsure Follow the link to share your opinion and see what your colleagues think!

Read More »

International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #52: Incretin Physiology in Health and Disease Part 2 of 6

Secretion of incretin hormones: The mucosa of the intestinal tract harbors a large number of endocrine cells that give rise to various peptide hormones. These include cholecystokinin, motilin, secretin, gastrin, gastric inhibitory polypeptide (GIP, also referred to as glucose-dependent insulinotropic polypeptide), glucagon-like peptide 1 (GLP-1), glucagon-like peptide 2, and peptide YY.

Read More »

Responding to Surveys

Why do you respond to DIC survey questions? 1. Because the question is interesting 2. Want to share my opinion 3. Want to see what my colleagues think 4. All of the above 5. I usually don't respond

Read More »

International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #51: Incretin Physiology in Health and Disease Part 1 of 6

The incretin effect in health: The idea that gastrointestinal factors contribute to the control of postprandial glucose regulation dates back to the beginning of the twentieth century, when Moore and colleagues reported reductions in glucosuria after the oral administration of gut extracts xin patients with juvenile diabetes. Even though it is questionable whether these glucose-lowering effects were really attributable to the incretin activity of the extract (which is unlikely, because most gastrointestinal peptide hormones are inactivated by the gastric acid), this report can be considered as the first description of an incretin-like effect.

Read More »

Type 2 Treatment Preferences

Which treatment do you feel most comfortable with for type 2 patients? 1. DPP-4 2. GLP-1 3. SGLT-2 4. Sulfonylurea 5. TZD 6. Insulin Follow the link to share your opinion and see what your colleagues think!

Read More »

Time Will Tell What Patient Will Do

Male, 21 years of age has class III obesity, binge eating disorder, fatty liver, and asthma, and was recently diagnosed with type 2 diabetes. It is his freshman year at a college away from home. He eats in the cafeteria, and has no refrigerator or stove in his room. He visits today after not taking metformin or GLP-1 agonist since at starting school. He is under a lot of stress and states the food at school is terrible, unhealthy, and not diabetes-friendly at all. Note, he has been taught a lower carb meal plan. He says he is not taking Glucophage or Victoza; each of them at low doses gives him terrible diarrhea. He states he checks his glucose twice a week, with fastings in the 90-100 range. He is up 10 pounds since our last visit in September.

Read More »

International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #50: Biosynthesis, secretion, and action of glucagon Part 4 of 4

Glucagon and diabetes: Plasma levels of glucagon have been found to be increased in all experimental and clinical forms of diabetes mellitus. This disturbance undoubtedly contributes to the hyperglycemia of the disease and excessive ketogenesis of diabetic coma. Numerous studies have shown that failure of glucagon suppression contributes to postprandial hyperglycemia in type 1 and type 2 diabetes.

Read More »